Article Text

Download PDFPDF

Epidemiology poster session 1: STI trends: HPV
P1-S1.51 Prevalence of anogenital Warts among STD clinic patients-STD surveillance network, USA, January 2010–September 2010
  1. E Llata1,
  2. R Pugsley2,
  3. I Tabidze3,
  4. L Asbel4,
  5. K Bernstein5,
  6. R Kerani6,
  7. J Schwebke7,
  8. L Longfellow8,
  9. C Mettenbrink9,
  10. S Guerry10,
  11. J Zenilman11,
  12. E Klingler12,
  13. H Weinstock1
  1. 1CDC, Atlanta, USA
  2. 2Virginia Department of Health, Richmond, USA
  3. 3Chicago Department of Public Health, Chicago, USA
  4. 4PDPH, Division of Disease Control, USA
  5. 5San Francisco Department of Public Health San Francisco, USA
  6. 6Public Health - Seattle & King Co, Seattle, USA
  7. 7University of Alabama, Birmingham, Birmingham, USA
  8. 8Louisiana Office of Public Health, Metairie, USA
  9. 9Colorado Department of Health, Colorado, USA
  10. 10LA County Dept of Public Health, Los Angeles, USA
  11. 11Johns Hopkins School of Medicine, Baltimore, USA
  12. 12NYC department of Health and mental hygiene, New York City, New York, USA


Background STD clinics routinely provide diagnostic and treatment services for anogenital warts. With the availability and increasing use of a highly effective quadrivalent vaccine against the HPV types associated with 90% of anogenital warts, the impact on patients presenting with anogenital warts to STD clinics may be significant. To be positioned to estimate the population-level impact of HPV vaccine on STD clinics, we conducted a baseline cross sectional analysis of patients with anogenital wart-related visits.

Methods We reviewed STD clinic data collected on patients seen by a clinician from 1 January 2010 to 30 September 2010 in 11 sites (38 clinics) participating in the STD Surveillance Network (SSuN)—Seattle, WA (1 clinic); San Francisco, CA (1); Los Angeles, CA (12); Denver, CO (1); Chicago, IL (5); New Orleans, LA (1); Birmingham, AL (1); Richmond, VA (3); Baltimore, MD (2); Philadelphia, PA (2); New York City, NY (9). SSuN uses a collaboratively developed protocol to collect demographic, risk behaviour, and clinical data on all patients with anogenital warts at participating STD clinics. The unit of analysis was unique patients; patients were considered to have anogenital warts if warts were identified at any visit.

Results Among SSuN sites, 3–13% (median 4%) of STD clinic patients had anogenital wart-related visits, with 5063 patients presenting for 6989 visits. Among patients with anogenital warts, 20% of the patients had multiple anogenital warts-related visits (range 2–26 visits). Overall, the median prevalence rate was 2% (range 1–5%) for women and 6% (range 4–22%) for men. By age and sex, median prevalence rates were highest among women aged 20–24 at 3% (range 1–7%) and among men aged 25–29 at 8% (range 5–25%). Among men who have sex with men (MSM), the median prevalence was 7% (range 4–18%) and among men who have sex with women only (MSW) it was 6% (range 3–23%). Of patients with anogenital warts, 40% were African American, 32% were white, 21% were Hispanic compared to all clinic patients who were 58% African American, 18% white, and 18% Hispanic. 59% received treatment and most treatment (97%) was provider applied.

Conclusions The prevalence of anogenital warts among women is low in STD clinics. It may thus be difficult to monitor the impact of the HPV vaccine in women in these settings. However, the higher prevalence in MSM and MSW suggest that these clinics may provide settings in which to monitor anogenital warts in men.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.